Biotechnology Reagents Market is an expert and inside-out market report that spotlights on market share, potential deals volume, driving portions and geological investigation of Biotechnology industry. It additionally contains the drivers and limits for the market that are gotten from SOWT examination, and furthermore demonstrates what all are the ongoing Biotechnology Reagents Market advancements, product launches, joint endeavors by the few key players and brands that are driving the market are by foundational organization profiles. It demonstrates that the ascent in market is for the most part credited to the rising development of the relevant enterprises and the resulting ascends popular of uses.

For More Details Get A Sample Copy Of This Biotechnology Reagents Market Report: https://databridgemarketresearch.com/request-a-sample/?dbmr=global-biotechnology-reagents-market

Introduction

This Biotechnology Reagents report introduce definition, classification, specification and application, market overview, market dynamics, market segmentation, raw materials, Industry policies, etc.

Analysis of the market

This Biotechnology Reagents report utilizes different types of the analysis of the market like SWOT analysis, Ports Five analysis which examines weakness, threats, drivers and restraints of the market.

Regional analysis of the market

This Biotechnology Reagents report focuses on key regions such as North America, South America, Asia and Pacific region, Middle east and Africa and Europe

Segmentation of the market

This Biotechnology Reagents report has been divided into type, application, geographical landscape with production Consumption, revenue, market share and growth rate of the Biotechnology Reagents market.

Sub Segments:

By Geography

North America (U.S., Canada, Mexico)

South America (Brazil, Argentina, Rest of South America)

Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe)

Asia-Pacific ( Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia Pacific)

Middle East & Africa (South Africa, Egypt, Saudi Arabia, United Arab Emirates, Israel, Rest of Middle East & Africa)

To Get An Idea About The Biotechnology Reagents Report, Avail The TOC Here: https://databridgemarketresearch.com/toc/?dbmr=global-biotechnology-reagents-market

Key Market Competitors:

Few of the major competitors currently working in the biotechnology reagents market are Abbott, Agilent Technologies Inc., Danaher, BD, Bio-Rad Laboratories Inc., General Electric, bioMrieux SA, LONZA, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Hoefer, Inc., Meridian Bioscience, Inc., PerkinElmer Inc., Merck KGaA, Promega Corporation, Quality Biological, Siemens AG, Bio-Techne, TAKARA HOLDINGS INC., Sysmex Corporation, Tosoh Corporation, WATERS, W. R. Grace & Co.-Conn., Ortho Clinical Diagnostics, Olympus Corporation and Fitzgerald Industries International among others.

What are the demands provided in the market?

This Biotechnology Reagents report focuses on the demands of the clients that helps to establish their business successfully. It also provides the guidance to overcome the upcoming obstacles by providing the unbiased picture of the market in the precise manner.

Which factors does this Biotechnology Reagents report includes?

This Biotechnology Reagents report includes a historic data and analysis of the key industry, six year forecast of the market and emerging trends, An assessment of the competitive landscape and market shares for major companies and much more

Conclusion:

The data included in this Biotechnology Reagents report is reliable, thoroughly researched and verified by the research analyst. It keeps you a step ahead by providing up dated information regarding the Industry which will help you to make faster and better decisions.

Want Full Report? Make Inquiries For Your Custom Requirements: https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-biotechnology-reagents-market

About Us

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing Corporatesales@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:Corporatesales@databridgemarketresearch.comhttps://databridgemarketresearch.com

Read the original here:
Biotechnology Reagents Market Analysis, International Marketing, Research Report With Top Industry Players - Galus Australis

We need home-grown scientific, technological and innovation revolution to wean ourselves from dependency on foreign simple technologies.

OPINION | BIOTECHNOLOGY

By Arthur Makara

I would like to appreciate your continuous, relentless efforts to harness science, technology and innovation in Uganda for socio-economic transformation.

We, scientists appreciate your recent intervention by creation of a fully-fledged Ministry of Science, Technology and Innovation (MoTI) and choosing for it a competent Minister Hon. Dr. Elioda Tumwesigye.

As the Ministry puts its foot on the ground, it needs your continuous support to build this sector that is a cornerstone of Ugandas transformation into a middle status economy in the near future. Your Excellency, as the Minister of Science and Technology started his work, one of the tasks the Minister of Finance, Planning and Economic Development was more than happy to pass over to him is the National Biotechnology and Biosafety Bill 2012.

This is because the issues of science had been largely a burden to the Ministers in the Ministry of Finance. Whereas Honorable Kasaija had come to appreciate the science the bill is meant to regulate there are other Ministers in the Ministry of Finance that irrespective of it being their responsibility to understand it, chose the anti-science stance, and continue to mobilize against this Government bill. This is not in line with Government Policy which was approved by Cabinetthe National Biotechnology and Biosafety Policy 2008.

Moreover, they are in cohort with foreign forces led by one Opiyo Oloya based in Toronto, Canada who irrespective of living in a Country that has immensely developed due to technological advancements, fails to appreciate and later alone borrow progressive lessons for Uganda from what goes on around him, only choosing to advance the interests of a the burgeons of the developed world, whose hidden interest is to keep Africa poor through the organic and small-scale farmer movements.

Oloya and his extensions in Uganda, the anti-science activist groups are now thrown in a state of confusion because of your clear supportive position of the enactment of the National Biotechnology and Biosafety Bill into law.

They thrive on spreading misinformation to the largely ignorant and gullible members of the public including some legislators do understand that it is scientific advancements that transform societies. It is the science outcomes from China, India, Korea, USA, Brazil, Europe and India that we consume on a daily basis, making our economies in Africa very weak due to hemorrhage of our currencies.

We need home-grown scientific, technological and innovation revolution to wean ourselves from dependency on foreign simple technologies, and to strengthen our currency through more local consumption and more exports.

We are markets for the developed economies, thus, they support anti-progress propaganda. I appreciate your recent interest in supporting youth groups, to sharpen up their skills and to improve on quality of home-made products. That is the right way to go in the direction of transformation.

Your Excellency, Opiyo Oloya published a veiled article against the National Biotechnology and Biosafety Bill on Wednesday 26th July in the New Vision covering it with the Tea estates in Kabalore and Kyenjojo preferring to call it organic Ugandan tea. He made a false and scientifically disputable claimdrink Ugandan tea, live longer.

And advocates that that should be the brand for Ugandan tea. Whereas this could be potentially true, Opiyo Oloya has no capacity to generate data to support this claim. It has to be scientists to do it, yet he does not trust them. For that brand to stand, it has to be backed by scientific evidence, as other countries will protest against it.

Moreover, I got surprised that Opiyo Oloya could appreciate large-scale commercial farming of any crop, yet he is a champion of small-scale, his grand-mother chicken type of agriculture. He and his anti-science allies are vehemently opposed to large-scale commercial farming preferring to call it monoculture, yet Ugandan policy is to transform from subsistence to commercial agriculture.

So, which policy are they advancing?

Now had Mr. Opiyo Oloya forgotten that the tea he was praising is a monoculture? Mr. Opiyo Oloya knows well that Your Excellency, you are too informed to be confused with his rhetoric, and that is why he is veiling his propaganda against the National Biotechnology and Biosafety Bill 2012 under Mukwano and Igara tea.

He also knows clearly that Ugandan tea is not organic, if we go by the definition of the global organic movement. The tea estate owners have not claimed that their tea is organic but he is pushing that narrative to fit his ill-convened interests. The tea estates owners apply fertilizers, they spray against tea diseases tea leaf rot caused by fungi Corticium invisum and C. thae), the tea red leaf rust caused by fungus Cephalarus mycoidea, black root caused by fungus Rosellina areuata.

These are controlled by use spraying with of large quantities of fungicides. Tea also has pests and vermin such as mites, leafhoppers, aphids and snakes that are controlled through spraying of pesticides and acaricides. These sprays are done at regular intervals or as and when such diseases and pests become rampant.

Ugandan tea is therefore referred to as conventional tea in the organic world. And the biotech revolution that Opiyo Oloya and his allies in Uganda are fighting has potential to make the Ugandan tea to be grown more organicallyparticularly if diseases and pests of tea are addressed through breeding of quicker maturing, disease resistant and robust tea verities, lesser pests and fungicides will be used on it. The primary strategy of Oloya and some uninformed leaders is to block any opportunity for this to be realized in order to serve their private interests.

Your Excellency, we in the science world appreciate the fact that you understand the intensions of such groups and individuals. We acknowledge and appreciate the remarks in support of science the science of biotechnology that you made when you were opening the 25th Source of the National Agricultural and Trade show in Jinja on Tuesday 18th July 2017.

We are comforted by the fact that with your foresighted leadership, the farmers will soon start benefiting from the efforts of your scientists through crop improvement after that enactment of the National Biotechnology and Biosafety Bill into law that will guide and regulate their work. Oloya the expert of everything and his anti-science allies should be ignored for a brighter future of Uganda.

For God and My Country.

The writer is the Executive Director of the Science Foundation for Livelihoods and Development

Read this article:
Open letter to president on biotechnology bill - New Vision

Note: MSU's programs in the biological sciences are distributed across multiple departments. MSU does not have a single Department of Biology. For additional options see Biological Sciences at MSU.

Modern research in cellular and molecular biology and its resultant technology offers unparalleled opportunities to provide solutions to our society's most urgent problems in human and animal health, agriculture, and environmental quality. The emerging biotechnology industries are involved in developing products to maintain biodiversity, restore soil and water quality, develop new pharmaceuticals to combat disease, decrease our dependence on nonrenewable resources, and improve food and fiber production. Students interested in microbiology, animal or plant science, biochemistry, and animal or human medicine will find challenging careers in the diverse areas of biotechnology in either an academic or industrial setting. Students successfully completing a biotechnology curriculum will also be prepared to enter graduate or medical professional schools for further study.

The Bachelor of Science in Biotechnology is an interdisciplinary degree that spans two academic departments: Microbiology and Immunology and Plant Sciences/Plant Pathology. Students will choose an area of emphasis in plant oranimal/microbial systems for upper-division coursework. Students will beassigned faculty advisors depending on the chosen option.

Go here to read the rest:
Biotechnology < Montana State University

Shares ofPuma Biotechnology Inc (PBYI) is moving on volatility today1.99% or 1.60 from the open.TheNASDAQ listed companysaw a recent bid of82.15 on627761 volume.

There are various factors to examine when looking at what spurs growth in the stock market. Many investors will monitor macro-economic factors that influence the price of shares. Some of these factors include the overall condition of the economy and market sentiment. Following the macro factors, investors may employ a top down approach when viewing the equity markets. This may include starting with a sector poised for growth and filtering down to specific stock that meet the investors criteria. Another way to approach the stock market is to view the micro-economic factors that influence stocks. This may include studying company profits, news, and the competence of overall management. Investors will often try to piece together all the different information available in order to select stocks that will have a positive impact on the long-term strength of the portfolio.

Digging deeping into the Puma Biotechnology Inc (PBYI) s technical indicators, we note that the Williams Percent Range or 14 day Williams %R currently sits at -59.16. The Williams %R oscillates in a range from 0 to -100. A reading between 0 and -20 would point to an overbought situation. A reading from -80 to -100 would signal an oversold situation. The Williams %R was developed by Larry Williams. This is a momentum indicator that is the inverse of the Fast Stochastic Oscillator.

Puma Biotechnology Inc (PBYI) currently has a 14-day Commodity Channel Index (CCI) of -34.06. Active investors may choose to use this technical indicator as a stock evaluation tool. Used as a coincident indicator, the CCI reading above +100 would reflect strong price action which may signal an uptrend. On the flip side, a reading below -100 may signal a downtrend reflecting weak price action. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal.

Currently, the 14-day ADX for Puma Biotechnology Inc (PBYI) is sitting at 40.95. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would support a strong trend. A value of 50-75 would identify a very strong trend, and a value of 75-100 would lead to an extremely strong trend. ADX is used to gauge trend strength but not trend direction. Traders often add the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) to identify the direction of a trend.

The RSI, or Relative Strength Index, is a widely used technical momentum indicator that compares price movement over time. The RSI was created by J. Welles Wilder who was striving to measure whether or not a stock was overbought or oversold. The RSI may be useful for spotting abnormal price activity and volatility. The RSI oscillates on a scale from 0 to 100. The normal reading of a stock will fall in the range of 30 to 70. A reading over 70 would indicate that the stock is overbought, and possibly overvalued. A reading under 30 may indicate that the stock is oversold, and possibly undervalued. After a recent check, the 14-day RSI for Puma Biotechnology Incis currently at 45.59, the 7-day stands at 47.11, and the 3-day is sitting at 67.10.

Shares ofTiffany & Co (TIF) aremoving on volatility today1.35% or 1.19 from the open.TheNYSE listed companysaw a recent bid of 89.30 and626967shares have traded hands in the session.

Stock analysis typically falls under the two main categories of fundamental and technical. Fundamental analysis involves diving into company financials. Fundamental analysts study how the company is performing in order to determine whether or not the stock is ready to run. With this type of analysis, investors will be looking at balance sheet strength and gauging how much money the company is giving back to shareholders. After crunching all the numbers, investors can use the information to calculate ratios to help determine if the company is properly valued and worth adding to the portfolio. Technical analysis relies on charting historical stock prices in order to define trends and patterns. The buying and selling of stocks using only technical analysis typically removes any concern for how the company is fairing or even what it actually does. Some indicators that technical analysts use can be super simple and others can be highly complex. Many investors will attempt to study both technicals and fundamentals with the goal of gaining greater knowledge of where the stock has been, and where it might be going.

Taking a deeper look into the technical levels ofTiffany & Co (TIF), we can see thatthe Williams Percent Range or 14 day Williams %R currently sits at -75.72. The Williams %R oscillates in a range from 0 to -100. A reading between 0 and -20 would point to an overbought situation. A reading from -80 to -100 would signal an oversold situation. The Williams %R was developed by Larry Williams. This is a momentum indicator that is the inverse of the Fast Stochastic Oscillator.

Tiffany & Co (TIF) currently has a 14-day Commodity Channel Index (CCI) of -111.90. Active investors may choose to use this technical indicator as a stock evaluation tool. Used as a coincident indicator, the CCI reading above +100 would reflect strong price action which may signal an uptrend. On the flip side, a reading below -100 may signal a downtrend reflecting weak price action. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal.

The RSI, or Relative Strength Index, is a widely used technical momentum indicator that compares price movement over time. The RSI was created by J. Welles Wilder who was striving to measure whether or not a stock was overbought or oversold. The RSI may be useful for spotting abnormal price activity and volatility. The RSI oscillates on a scale from 0 to 100. The normal reading of a stock will fall in the range of 30 to 70. A reading over 70 would indicate that the stock is overbought, and possibly overvalued. A reading under 30 may indicate that the stock is oversold, and possibly undervalued. After a recent check, Tiffany & Cos 14-day RSI is currently at 39.93, the 7-day stands at 36.60, and the 3-day is sitting at 42.24.

Currently, the 14-day ADX for Tiffany & Co (TIF) is sitting at 20.66. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would support a strong trend. A value of 50-75 would identify a very strong trend, and a value of 75-100 would lead to an extremely strong trend. ADX is used to gauge trend strength but not trend direction. Traders often add the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) to identify the direction of a trend.

See the article here:
Puma Biotechnology Inc (PBYI) Shares Needle Moving 1.99% - Morgan Research

LAS VEGAS, August 15, 2017 /PRNewswire/ --

The healthcare sector is made up of several different industries, from pharmaceuticals to biotechnology to health insurance. Making predictions in this sector can be difficult as there are many variables working with and against each other at one time. It's important to track both negative and positive trends in healthcare companies. Investors who track these trends, make the best out of their predictions.

Certain trends in healthcare an investor should track include: the aging population and their healthcare needs, personalized medicine, the global reach of certain diseases, obesity and diabetes epidemic, and of course, technological advances. All of these trends mean different things in healthcare stock. Biotech companies are working tirelessly to address specific trends in human health, identifying the companies who are working with healthcare trends is key.

Some such companies include: Endonovo Therapeutics, Inc. (OTC: ENDV), Juno Therapeutics, Inc. (NASDAQ: JUNO), Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), Genocea Biosciences, Inc. (NASDAQ: GNCA), and TherapeuticsMD, Inc. (NYSE: TXMD)

Endonovo Therapeutics, Inc. (OTCQB: ENDV)

Market Cap: $7.3M, current share price: .028

ENDV is an innovative biotechnology company implementing a bioelectronic approach to regenerative medicine. They are addressing several healthcare trends with their electroceutical platform, which is a non-invasive, non-implantable device for treating inflammatory conditions in vital organs. Through the innovative research at ENDV, they are addressing most of the major healthcare trends by developing therapies to treat the aging population and addressing obesity and the complications that it entails, such as peripheral artery disease, heart disease, diabetic kidney disease and non-alcoholic steatohepatitis (NASH). Additionally, ENDV is working to address global diseases, kidney disease, and organ failure.

Tracking ENDV and their work in research and development (R&D) is something anyone interested in healthcare or biotech stocks should do. As their research correlates and ebbs and flows with healthcare trends. Some highlights regarding ENDV's R&D are below:

As ENDV moves forward and inches closer to announcing the results of their pre-clinical studies across their diverse technology platform, you'll want to stay up-to-date with their successes.

Other healthcare and biotech companies to review

Juno Therapeutics, Inc. (JUNO)

Market Cap: $3.021B, current share price: 28.30

JUNO, a clinical-stage cell immunotherapy company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer, has achieved recent milestones with its collaboration with Editas Medicine, Inc. (EDIT) This collaboration began over two years ago, the two companies are pursuing three research programs that aim to combine Editas Medicine's genome editing platform with Juno's CAR and TCR technologies.

Their most recent achievement relates to the improvement in the ability of T cells to overcome the tumor microenvironment. Editas Medicine will receive $2.5 million for achieving this milestone.

Eleven Biotherapeutics, Inc. (EBIO)

Market Cap: $35.2M, current share price: 1.425

EBIO is a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform. They announced this week that they'll be hosting a live conference call to announce their Q2 financial results.

This is scheduled for 8:00 a.m. ET on Monday, August 14, 2017. To access the conference call, please dial (844) 831-3025 (domestic) or (315) 625-6887 (international) at least five minutes prior to the start time and refer to conference ID 63779857.

Genocea Biosciences, Inc. (GNCA)

Market Cap: $112.74M, current share price: 3.955

Similarly to JUNO and EDITS collaboration on moving research forward regarding T cells, GNCA's lead candidate is a novel T cell-directed immunotherapy for genital herpes. Today marks a horrible day for GNCA's performance on the stock market. GNCA's shares closed down 7.42% on Thursday with a little over 600,000 shares traded. The company reported second quarter financial results this week and reported a loss of $15.4 million.

On a per share basis, this was a loss of 54 cents while Wall Street was only expecting a loss of 46 cents. Keep a lookout for this stock as its performance is expected to continue to plummet.

TherapeuticsMD, Inc. (TXMD)

Market Cap: $1.15B, current share price: 5.630

TXMD, an innovative women's healthcare company, just received a formal General Advice Letter from the FDA stating that an initial review has been completed and requesting that the Company submit the additional endometrial safety information to the NDA for TX-004HR on or before September 18, 2017.

This is great news for TXMD although they've been ranked negatively in the HealthCare Sector. Investors who seek profit from falling equity prices should target TXMD. Short interest is extremely high for TXMD with more than 20% of shares on loan.

Microcap Speculators

Email: rel="nofollow">info@microcapspecualtors.com

Phone: +1-702-720-6310

Website: http://microcapspeculators.com/

DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Please use this link:http://microcapspeculators.com/disclaimer/

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.

Media Contact

FN Media Group, LLC

rel="nofollow">editor@financialnewsmedia.com

+1-(954)-345-0611

Continued here:
Tracking Trends in Biotechnology - Markets Insider

On May 4, 2017, Puma announced the resignation of its Senior Vice President, Regulatory Affairs, effective as of May 15, 2017, less than two weeks before the FDA's scheduled review of neratinib. On May 5, 2017, Fox Business published an article reporting that a large number of patients taking neratinib suffered from severe side effects, posing a safety risk for the drug.

Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.

If you own Puma shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Robert I. Harwood, Esq. Benjamin I. Sachs-Michaels, Esq. Harwood Feffer LLP 488 Madison Avenue New York, New York 10022 Phone Numbers: (877) 935-7400 (212)935-7400 Email: bsachsmichaels@hfesq.com Website: http://www.hfesq.com Follow us on Twitter: @HarwoodFeffer

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-puma-biotechnology-inc-300460923.html

SOURCE Harwood Feffer LLP

http://www.hfesq.com

The rest is here:
Harwood Feffer LLP Announces Investigation of Puma Biotechnology, Inc. - PR Newswire (press release)

Barron's

ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain Barron's Meanwhile the SPDR S&P Biotech ETF (XBI), the SPDR S&P Pharmaceuticals ETF (XPH), and the First Trust NYSE Arca Biotechnology Index (FBT) fell about 2.7% apiece. The AHCA could have both positive and negative impact on pharma and biotech, but ... Direxion Daily S&P Biotech Bear 3X Shares (LABD): The Quick Guide to LABDInvestorplace.com all 38 news articles »

See original here:
ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain - Barron's

Market SummaryFollow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Puma Biotechnology Inc (PBYI) had a good day on the market for Friday August 11 as shares jumped 8.96% to close at $78.45. About 1.12 million shares traded hands on 9,325 trades for the day, compared with an average daily volume of 1.46 million shares out of a total float of 36.97 million. After opening the trading day at $71.85, shares of Puma Biotechnology Inc stayed within a range of $78.50 to $71.14.

With today's gains, Puma Biotechnology Inc now has a market cap of $2.9 billion. Shares of Puma Biotechnology Inc have been trading within a range of $98.85 and $28.35 over the last year, and it had a 50-day SMA of $85.99 and a 200-day SMA of $50.43.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc is based out of Los Angeles, CA and has some 160 employees. Its CEO is Alan H. Auerbach.

For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

Puma Biotechnology Inc is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE:The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

See the rest here:
Puma Biotechnology Inc (PBYI) Soars 8.96% on August 11 - Equities.com

Two years after the $9 billion start-up unicorn Theranos crumbled, Silicon Valley still appears to be struggling to learn its lesson when it comes to health and medical start-ups. Improbable-sounding companies continue to turn up with tens of millions of dollars in funding, no published research to back them up, and nothing but criticism from scientists.

Venture-capital firms insist that the standard that needs to be met for investment is much higher for medical start-ups, which must prove that their technology works with data, not just a pitch. And yet somehow, when these start-ups finally surface to public consciousness, they dont appear to pass even the most basic smell test with literally any experienced researcher in the field.

There is a pervasive sense in Silicon Valley, bolstered by ten years of world-conquering success, that any sufficiently intelligent, sufficiently driven person can will what they want.

But the move fast and break things mantra that has helped Silicon Valley disrupt countless industries over the last two decades is more dangerous when applied to medical scienceThe things being broken by health start-ups are laws of science and ironclad guidelines for research. When a health start-up moves fast and breaks things, it can directly result in the death, dismemberment, and injury of real people.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:Why Silicon Valley Keeps Getting Biotechnology Wrong

For more background on the Genetic Literacy Project, read GLP on Wikipedia

See the original post here:
Why so many biotechnology start-ups, like Theranos, fail | Genetic ... - Genetic Literacy Project

DUBLIN, Apr. 24, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Biotechnology Reagents Market 2017-2021" report to their offering.

Research and Markets Logo

The global biotechnology reagents market to grow at a CAGR of 10.13% during the period 2017-2021.

The report, Global Biotechnology Reagents Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Ready-to-use reagents help minimize calculation, dilution, and pipetting errors. They reduce the duration of the diagnostic procedure and prevent contamination of samples. These factors have resulted in the demand for ready-to-use reagents among clinical laboratories and hospitals.

According to the report, the biotechnology industry is spending a huge amount on R&D to innovate new techniques and technologies. The companies are more focused to improve the products, their quality, and standards. The biotech companies are majorly spending on protein synthesis, drug assessment, therapeutics, DNA and RNA analysis, and cell culture applications. Biotechnology reagents are used in all the processes.

Further, the report states that biotechnology instruments are often complex and require sophisticated software for various measurement procedures. To operate the instruments and analyze a sample, the user must have a significant level of training with not only the method and the instrument but also the software required to run the analysis and the collection of data.

Key vendors

Other prominent vendors

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market landscape

PART 06: Market segmentation by technology

PART 07: Market segmentation by application

PART 08: Geographical segmentation

PART 09: Decision framework

PART 10: Drivers and challenges

PART 11: Market trends

PART 12: Vendor landscape

PART 13: Key vendor analysis

PART 14: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/dqbbgf/global

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-biotechnology-reagents-market-to-grow-at-a-cagr-of-1013-by-2021---rising-demand-for-ready-to-use-reagents-among-clinical-laboratories--hospitals---research-and-markets-300443626.html

See the article here:
Global Biotechnology Reagents Market to Grow at a CAGR of 10.13 ... - Yahoo Finance

LONDON, UNITED KINGDOM--(Marketwired - Apr 24, 2017) - Planda Biotechnology, Inc. ( OTCQB : PLPL ) ("Planda" or "the Company"), producer of the highly bioavailable Phytofare Catechin Complex, today announced that NutriBullet SuperFood Fat Burning Boost featuring Planda's Phytofare Catechin Complex will be available at retail outlets across the United States as early as May 2017.As announced last November, Capital Brands, the makers of NutriBullet SuperFoods, will now be featuring Planda's Phytofare Catechin Complex as the active ingredient in their product, SuperFood Fat Burning Boost.Capital Brands is expected to launch the revised product containing Phytofare with their retailers and on their website (nutriliving.com) as early as next month.

Callum Cottrell-Duffield, Chief Operating Officer for Planda Biotechnology, commented, "We are excited to have Phytofare associated with such a fantastic brand as Nutribullet. Their use of Phytofare as an active ingredient in their reformulation is a clear indication of their commitment to use only the best ingredients to ensure that their customers receive a supremely effective product. It is also testimony to our shareholders that we are indeed on the right track and that our Phytofare ingredients are game changers for the supplement industry."

NutriBullet has formulated specialized, plant-based SuperFood products using a variety of plant proteins,prebiotic and other dietary fibers, proprietary spice blends, and other unique ingredients etc. that can be easily combined into healthy smoothies using their industry-leading nutrient extraction blenders. The company uses all GMO-free ingredients sourced from the world's most reputable farms that undergo extensive testing for purity, effectiveness and flavor.

Planda operates an 8,000-acre estate in Mpumalanga, South Africa, where it grows and processes the green tea used in its Phytofare products. The company uses solar power for on-site housing and organic, sustainable farming practices to ensure the highest quality. Between the farm and factory, the company provides employment for hundreds of local families and, through profit sharing and rental payments, is able to bring economic value to the Zulu community.

About Capital Brands LLC Capital Brands LLC and its subsidiaries create, produce, and sell NutriBullet blenders as well as SuperFood formula mixes and other accessories for their blenders that help give the consumer the best possible health benefits using only the best and most quality ingredients available. The company focuses on nutrient extraction in order to deliver the most nutrients possible from food and other ingredients to increase the health of people everywhere. For more information, please visit https://www.nutribullet.com/."NutriBullet" and "SuperFood Fat Burning Boost" are the registered trademarks of Capbran Holdings, LLC.

About Planda Biotechnology, Inc. Planda Biotechnology, Inc. and its subsidiaries develop highly phyto-available extracts. Planda Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.

View original post here:
NutriBullets SuperFood Boost Featuring Plandai Biotechnology's ... - Yahoo Finance

Post Analyst

Puma Biotechnology (PBYI) Earns News Sentiment Rating of 0.44 Transcript Daily Puma Biotechnology logo Press coverage about Puma Biotechnology (NYSE:PBYI) has been trending positive on Monday, Alpha One reports. The research group, a unit of Accern, ranks the sentiment of media coverage by analyzing more than 20 million ... Puma Biotechnology Inc Risk Points versus Health Care - CMLvizCML News Candriam Luxembourg S.C.A. Has $5.748 Million Position in Puma Biotechnology Inc (PBYI)Markets Daily Puma Biotechnology Inc (PBYI) Earns "Buy" Rating from Stifel NicolausBBNS Post Analyst -Sports Perspectives -The Cerbat Gem all 22 news articles »

Read the original post:
Puma Biotechnology (PBYI) Earns News Sentiment Rating of 0.44 - Transcript Daily

FARGO, N.D. Those attending the recent International Sugarbeet Institute in Fargo got a glimpse of what the future of agriculture is going to look like. That peek into the future was made possible by the keynote speaker Robert Fraley, Ph.D., the executive vice president and chief technology officer at Monsanto. In addition, he is often recognized as the father of agricultural biotechnology.

In his position, Fraley has his finger on the pulse of agricultures future, which he claims is very strong and promising.

Ive been doing this at Monsanto for 37 years, he said, and I would tell you today that the amount of science coming into agriculture is just stunning. I helped invent GMO. Today we are talking about the second or third generation beyond GMO.

From those first Roundup Ready soybeans and BT cotton approved about 20 years ago, a wide variety of crops have been added to the list such as corn, canola, sugarbeets and alfalfa, along with many other lesser crops, he noted.

Fraley feels the most important advancement of adapting GMO technology is the ability to use germplasm from all around the world.

This means the next improvement in corn could easily come from a breeder in South America or the next advancement in soybeans could come from a plant breeder in China. Now that we have every gene sequenced in these plants, each one of these breakthroughs can quickly be bred in.

Monsanto is currently spending over half of its research and development budget on breeding crops better with these new technologies, he said.

One of the biggest advancements to be used in the last two or three years is what is known as gene editing, and what is remarkable about it is the fact it isnt a GMO, even though it has the power to literally change every gene and do it in a very specific and precise way.

The distinction is, when we make a GMO, like a Roundup Ready sugarbeet, we have added a new gene to the sugarbeet, he said. In the case of gene editing, we are just precisely changing the genes that are there, but doing it in a way that gives us an enormous ability to improve the crop.

He listed several new products that Monsanto will soon be bringing to the market in an effort to make agriculture more productive and profitable.

Some would claim that only a few companies are involved in finding new products and services to bring to the ag industry. However, a study conducted by Fraley has shown that approximately 4,000 entities, both private and public, from around the world are working on a wide range of subjects ranging from the planting phase to the harvest phase of the industry.

Just considering the planting phase of agriculture, the survey shows over 325 companies are involved with planting equipment, over 525 with crop protection products and approximately 1,240 companies associated with fertilizers.

Over the last two years, investors in start-up companies, have invested over $10 billion in agriculture, Fraley said. There are literally a thousand new start-up companies involved in satellites, imagery and gene editing. It is a very dynamic area, with lots of new players coming in.

We are seeing the best of all worlds thousands of new startups and players coming in, and we are seeing some of the established players realize that they need to up their game, raise the ante and do more. And that is a really healthy thing.

The latest word on wheat

According to Fraley, wheat is the last major crop that has not seen the real benefits of biotechnology, molecular breeding or gene editing that we have seen for the other crops.

Monsanto, through its acquisition of WestBred and merger with Bayer, has started to do some of this work in wheat. The combination of the companies capabilities creates a pretty strong presence to be able to drive innovation in wheat.

I think that is one of the upsides from the business combination, he said, referring to the eventual merger of the two agribusiness firms.

Methods of winning acceptance of biotechnology

The final challenge Fraley issued to those attending his presentation is the need to communicate more. Today, less than 1 percent of the U.S. population is engaged in farming.

We are the 1 percent that needs to reach out, magnify our voices, and continually explain to consumers, politicians, the decision makers, the regulators the importance of agriculture innovation, he said. The consumers need to understand and can support and be comfortable with the kinds of innovations that we need to farm better, farm more profitable and to farm more sustainable.

This was the 55th annual International Sugarbeet Institute that brings together the growers and the allied industries that are engaged in sugarbeet production.

Original post:
Agriculture's biotechnology has a bright future | Regional News ... - Farm and Ranch Guide

Press conference in BelTA's press center

MINSK, 30 August (BelTA) Over $3 billion worth of biotechnology products have been made in Belarus in the last five years, BelTA learned from Emilia Kolomiyets, Director General of the R&D group Chemical Synthesis and Biotechnologies, Director of the Microbiology Institute of the National Academy of Sciences of Belarus (NASB).

According to the source, an essential breakthrough in biotechnologies has been secured in the last few years. Various kinds of biotechnology products worth over $3 billion were made in Belarus in the last five years. Over 170 modern biotechnologies were created over the course of five years. As many as 12 existing manufacturing facilities were upgraded. Eight centers and labs were established as well as nine new enterprises and 39 biotechnology manufacturing facilities.

White and green biotechnologies that cater to the production sector and agriculture are most advanced in Belarus. Those are primarily biodiesel and biogas. These areas are very actively developing. I think in the future efforts will focus on biofuel such as bioethanol and biobutanol. As far as agriculture is concerned, modern farming technologies are being created using biotechnology advances and techniques designed to improve productiveness, noted the director of the Microbiology Institute.

Certain accomplishments have been secured in the area of red biotechnology, which is related to biopharmaceutics and biomedicine. Cell biotechnologies, genome biotechnologies are widely used. Our microbe biotechnologies have moved on, in particular, the synthesis of ferments such as nucleic acids, which are vital for making pharmaceutical substances and ready-made medications. All of it allows us to create original medications, added Emilia Kolomiyets.

Microbial drug with various applications account for a considerable part of the biotechnology products made in Belarus. Agriculture uses biological crop protection agents, microbial fertilizers, probiotics, biological decontaminants, biological preservation agents for vegetable raw materials, ferment products, fodder protein, amino acids, and vitamins. Power engineering industry uses various kinds of biofuel such as biobutanol, bioethanol, biodiesel, and biogas. Healthcare industry uses raw materials for pharmaceutical industry, biopharmaceutic technologies, and diagnostic preparations. Food industry uses yeast, sugar substitutes, food additives, and organic acids.

View post:
Over $3bn worth of biotechnology products made in Belarus in last five years - Belarus News (BelTA)

The 56 rating InvestorsObserver gives to Chiasma Inc (CHMA) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 59 percent of stocks in the Biotechnology industry, CHMAs 56 overall rating means the stock scores better than 56 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Chiasma Inc (CHMA) stock is trading at $4.12 as of 11:22 AM on Wednesday, Apr 8, a gain of $0.59, or 16.71% from the previous closing price of $3.53. The stock has traded between $3.65 and $4.34 so far today. Volume today is high. So far 1,505,751 shares have traded compared to average volume of 341,128 shares.

To see InvestorsObserver's Sentiment Score for Chiasma Inc click here.

Continued here:
Industry Breakdown: Where Does Chiasma Inc (CHMA) Stock Fall in the Biotechnology Field? - InvestorsObserver

DUBLIN, Nov. 11, 2019 /PRNewswire/ -- The "Global Marine Biotechnology Market" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global marine biotechnology market is expected to grow significantly from USD 3,500.4 million in 2017 to USD 6,500.6 million in 2024, at a CAGR of 9.61% from 2018 to 2024.

The growth in the market is attributed to the rising usage of marine biotechnology in various industries, advances in drug discovery and growing expenditure in R&D activities. Moreover, increasing demand for eco-friendly products is further propelling the market growth.

Key findings from the report:

The years used for the assessment are as follows;

Key Topics Covered:

CHAPTER 1. Market Scope and Methodology1.1. Research methodology1.2. Research scope & assumptions1.3. List of data sources

CHAPTER 2. Executive Summary2.1. Marine Biotechnology- Market Snapshot

CHAPTER 3. Industry Analysis3.1. Market definition3.2. Market segmentation3.3. Key findings of the global marine biotechnology market3.4. Value chain analysis3.4.1. By end-use Industries3.5. Market opportunities & trends3.5.1. Increasing usage of marine biotechnology for the development of biofuels3.5.2. Rising investment and collaborations in translational research3.6. Market driver analysis3.6.1. Rising usage of marine biotechnology in various industries3.6.2. Advances in drug discovery3.6.3. Increasing demand for eco-friendly products3.7. Market restraint analysis3.7.1. Fluctuations in prices of crude oil3.7.2. Difficulty in sampling the huge diversity of resources

CHAPTER 4. Competitive Outlook4.1. Competitive analysis4.1.1. Industry Analysis-Porters five forces analysis4.1.2. Company Share Analysis4.2. Competitive factors

CHAPTER 5. Global Marine Biotechnology Market Size and Forecast (2014 - 2024)5.1. Global Marine Biotechnology Market, By Source5.1.1. Algae5.1.2. Annelids5.1.3. Bacteria5.1.4. Bryozoa5.1.5. Cnidaria5.1.6. Crustacea5.1.7. Fungi5.1.8. Echinoderms5.1.9. Fishes5.1.10. Molluscs5.1.11. Nemertinea5.1.12. Protozoa5.2. Global Marine Biotechnology Market, By Product5.2.1. Bio Active Substances5.2.2. Bio Material5.2.3. Others5.3. Global Marine Biotechnology Market, By Technology5.3.1. Isolation and Cultivation of Microorganisms5.3.2. Culture-Independent Techniques5.4. Global Marine Biotechnology Market, By Application5.4.1. Aquaculture and Food Products5.4.2. Environmental and Human Health5.4.3. Drug Discovery5.4.4. Pollution Remediation5.4.5. Wastewater & Waste Disposal5.4.6. Biofuels5.4.7. Others5.5. Global Marine Biotechnology Market, By End-user5.5.1. Food Industry5.5.2. Pharmaceutical and Biotech5.5.3. Cosmetics5.5.4. Chemical5.5.5. Energy5.5.6. Others

CHAPTER 6. Global Marine Biotechnology Market, By Geography6.1. North America Marine Biotechnology Market6.1.1. North America Marine Biotechnology Market, By Source (USD Million)6.1.2. North America Marine Biotechnology Market, By Product (USD Million)6.1.3. North America Marine Biotechnology Market, By Technology (USD Million)6.1.4. North America Marine Biotechnology Market, By Application (USD Million)6.1.5. North America Marine Biotechnology Market, By End-user (USD Million)6.1.6. North America Marine Biotechnology Market, By Country6.1.6.1. U.S.6.1.6.2. Canada6.1.6.3. Mexico6.2. Europe Marine Biotechnology Market6.3. Asia-Pacific Marine Biotechnology Market6.4. Centeral and South America Marine Biotechnology Market6.5. Middle East and Africa Marine Biotechnology Market

CHAPTER 7. Key Players and Strategic Developments7.1. Business Overview7.2. Product and Service Offering7.3. Financial Overview7.4. Strategic Developments

Story continues

Link:
Global Marine Biotechnology Markets Report 2019: Market is Expected to Grow from USD 3.5 Billion in 2017 to USD 6.5 Billion in 2024 - Yahoo Finance

There are plenty of explanations of what biotechnology is, but the simplest one is that it is a field of study where biology is the foundation on which different kinds of technology are developed. Biotechnology is the basis of many different kinds of research in the fields of environment, food science, robotics, agriculture and medicine.

The human involvement in manipulating their environment is now at remarkable levels. From the most basic direct organism manipulations such as fermenting beer and culturing bacteria to advanced nucleotide-based organ regeneration and animal cloning, our knowledge and technology has advanced far beyond what anyone wouldve expected just a decade ago.

But even before there was a name to call it by, biotechnology was in existence. Even something that people have been doing for centuries, like preservatives to keep food edible during winter, is a form of biotechnology. When around 6000 BC, fruit juice was first fermented to form alcohol, it was another instance of biotechnology. Of course, it has emerged as a science only recently.

About twenty years ago, the role of genetics in artificially creating proteins in a living being was discovered. DNA was discovered and molecular biology became a part of mainstream science. This was what gave rise to the study of biotechnology under that name.

The mid 80s brought a revelation in biotechnology genetic structures could be modified by careful combinations between animals and plants. This introduction to transgenic organisms also developed an area for further research into disease resistance and productivity rate increases. Modern biotechnology is used in a variety of ways and the medical and biological research fields have managed to get the most benefit out of it. The methods used have gone beyond ordinary genetic transfers, to include actual plant-generated pharmaceuticals and substance production for antibiotics and insulin.

Modern biotechnology is practiced in three different categories red, white and green. Red Biotechnology is when the genetically altered microorganisms are used to produce medical and pharmaceutical substances, such as proteins, vitamins, antibiotics and vaccines etc. Its also used in genome manipulation.

White Biotechnology is also known as bio-manufacturing and Grey Biotechnology. This is not yet a completely established field and involves manipulating live organisms to create important industrial chemicals. Some of the organisms used in these techniques include bacteria, enzymes, moulds and yeast.

Agricultural Biotechnology, also known as Green Biotechnology, is whats applied into creating better, fresher, more nutritious and longer-lasting agricultural produce. A traditional agricultural biotechnology example is how wheat varieties are cross-bred to produce a disease-resistant crop.

If you are looking for the latest biotech news then take a look at this great new website. Full of details about innovations for the biotech industry , you cant afford to miss it. New inventions, ideas and theories make great reading.

Photo By 3dman_eu from Pixabay

Continue reading here:
Evolving Biotechnology - Good Herald

Preparing competent, competitive, and ethical leaders, Azusa Pacifics new Master of Science in Biotechnology equips graduates to make significant contributions to and profoundly influence this emerging science field. Set to launch in fall 2017 with a cohort of 24, the advanced degree distinguishes itself from counterparts at other institutions by approaching the discipline from a distinctly Christian worldview and instilling in students the ability to synthesize human need, potential, and responsibility.

Graduates with this level of training find a wide-open marketplace eager to hire. Jobs in the biomedical industry show an upward trend throughout the country, and particularly in California, home to more than 50 percent of these companies. According to a 2014 report from Genetic Engineering and Biotechnology News, the industry expects significant job growth over the next decade in the areas of epidemiology, bioinformatics and genetic counseling, microbiology, biomedical engineering, and biomedical research. Nestled in the heart of the countrys second-largest cluster of bioscience businesses, APU offers students a distinct advantage that surpasses traditional internships and networking. A collaborative enterprise, this program partners APU with local bioscience companies, including Grifols Biologicals, Gilead Sciences, Johnson & Johnson, Allergan, and others. In addition to technical proficiency, APUs program also provides industry-critical skills, such as project and program management, communication skills, teamwork, business ethics, and leadership, which produces graduates who are productive employees on the first day of hire in a corporate setting.

Open to students and professionals with bachelors degrees in molecular or cellular biology, biochemistry, applied mathematics, statistics, engineering, or computer science, the M.S. in Biotechnology offers a unique approach to the field through the lens of Christian faith and imparts a clear understanding of how believers can participate in and provide guidance to the industry in a way that advances science and glorifies God.

Posted: June 12, 2017

Read the rest here:
New Master's Program Prepares Leaders in Biotechnology - Azusa Pacific University

BioTime to Present at 16 thNational Life Sciences and Biotechnology Week (MIXiii BIOMED)

BioTime, Inc.(NYSE MKT: BTX and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that BioTime, and its subsidiary Cell Cure Neurosciences Ltd., will be featured in two presentations at the 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED) on Wednesday, May 24, 2017 as part of the Regenerative and Cell Therapies track. The conference is being held at the David InterContinental in Tel Aviv, Israel, May 23-25, 2017.

Presentations will be held at 12:15 p.m. and 3:45 p.m. IDT in Hall B of the InterContinental, and will highlight both the companys technology and business model. Jim Knight, BioTime, Inc. Senior Vice President and Head of Corporate Development, will discuss the evolution of the BioTime group of companies during one of the presentations. A second presentation will focus on cell-based transplantation therapy in AMD patients. Each presentation will be followed by a panel discussion. More information about the conference program and presentations can be found here.

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what the company believes to be the worlds premier collection of pluripotent cell assets. The foundation of BioTimes core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. and OncoCyte Corporation, which BioTime founded and which, until recently, were majority-owned consolidated subsidiaries of BioTime.

BioTimecommon stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visitwww.biotimeinc.comor connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

Investor Contact: EVC Group, Inc. Michael Polyviou/Doug Sherk, 646-445-4800 mpolyviou@evcgroup.com;dsherk@evcgroup.com or Media Contact: JQA Partners, Inc. Jules Abraham, 917-885-7378 jabraham@jqapartners.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20170523005380/en/

Continue reading here:
BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED) - Stockhouse

Wednesday was a good day for stocks, and the Dow Jones Industrials and S&P 500 both climbed through milestone levels. Most market participants attributed the positive sentiment to the Federal Reserve, which released the minutes of its latest monetary policy meeting during the afternoon. The central bank revealed plans to clamp down on the size of its balance sheet, which it initially expanded in the aftermath of the financial crisis to provide liquidity to the bond market and additional stimulus to the U.S. economy. Investors were pleased that the Fed believes that it's no longer necessary to extend that level of monetary accommodation to the economy. In addition, some individual companies had extremely good news, and Abercrombie & Fitch (NYSE:ANF), Triumph Group (NYSE:TGI), and Puma Biotechnology (NASDAQ:PBYI) were among the best performers on the day. Below, we'll look more closely at these stocks to tell you why they did so well.

Shares of Abercrombie & Fitch climbed 6% in the wake of reports that the teen retailer might receive an acquisition bid from a consortium of investors. According to The Wall Street Journal(subscription required), industry peer American Eagle Outfitters (NYSE:AEO) and private equity company Cerberus Capital Management are looking at putting together a potential buyout offer for Abercrombie & Fitch, following speculation that other players in the industry might also be interested in consolidation. A&F has been dealing with takeover speculation for a while, and it has typically noted that any discussions wouldn't necessary translate into actual offers. Yet with Abercrombie set to release its first-quarter financial results Thursday, investors will want to see signs that the company can take care of its challenges on its own -- or else they'll start clamoring more loudly for a buyout to take place.

Image source: Getty Images.

Triumph Group stock soared over 30% after the company announced its fiscal fourth-quarter financial results and resolved a dispute with aircraft manufacturer Bombardier. The aerospace components and systems specialist said that sales fell 13% from year-ago levels, and it posted a GAAP loss of $126.8 million. With challenges in its aerospace structures business, Triumph has focused on amending contracts and addressing operational and financial challenges, and the company's transformation plan has led to improving free cash flow and cost savings. Investors were also happy that Triumph reached a settlement of all of its disputes with Bombardier. Triumph said that the agreement "resets the commercial relationship between [Triumph] and Bombardier and allows each of them to better achieve their business objectives going forward."

Finally, shares of Puma Biotechnology jumped 30%. The biopharmaceutical company earned a hoped-for approval from the U.S. Food and Drug Administration advisory panel looking at its neratinib candidate treatment for breast cancer. The panel voted 12 to 4 in favor of recommending the drug to the FDA, and although panelists expressed some thoughts about potentially limiting the size of the group of women eligible to use the drug, investors nevertheless took the news as a positive. The FDA still needs to make its own decision about Puma's drug, and it isn't bound by the opinion of the advisory panel. Nevertheless, today's recommendation moves Puma one step further to getting a big win under its belt, and shareholders recognized that fact with the second big move in the stock this week.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Read the original post:
Why Abercrombie & Fitch, Triumph Group, and Puma Biotechnology Jumped Today - Motley Fool